Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Транскатетерная имплантация аортального клапана с использованием бивалирудина у пациента с гепарининдуцированной тромбоцитопенией
Транскатетерная имплантация аортального клапана с использованием бивалирудина у пациента с гепарининдуцированной тромбоцитопенией
Комлев А.Е., Ромакина В.В., Имаев Т.Э. и др.
Транскатетерная имплантация аортального клапана с использованием бивалирудина у пациента с гепарининдуцированной тромбоцитопенией.
Consilium Medicum. 2020; 22 (1): 67–71
DOI: 10.26442/20751753.2020.1.200017
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Аннотация
Авторы приводят первое в отечественной литературе описание клинического случая успешной транскатетерной имплантации аортального клапана у пациента высокого хирургического риска с критическим аортальным стенозом и документированной гепарининдуцированной тромбоцитопенией 2-го типа с использованием прямого ингибитора тромбина бивалирудина. Освещаются ключевые вопросы патогенеза, клинико-инструментальной диагностики гепарининдуцированной тромбоцитопении, а также существующая на сегодняшний день доказательная база применения бивалирудина в качестве препарата для управляемой интраоперационной антикоагуляции при наличии противопоказаний к гепарину.
Ключевые слова: гепарининдуцированная тромбоцитопения, бивалирудин, транскатетерная имплантация аортального клапана..
In the paper the authors report the first in Russia clinical case of successful transcatheter aortic valve implantation in high-risk patient with critical aortic stenosis and verified heparin-induced thrombocytopenia type 2 with use of direct thrombin inhibitor bivalirudin. The key issues of pathogenetic and diagnostical issues of verified heparin-induced thrombocytopenia, and up-to-date clinical evidence of bivalirudin as alternative medication for the controlled procedural anticoagulation in the setting of contraindication for heparin use are highlighted in the literature review.
Key words: heparin-induced thrombocytopenia, bivalirudin, transcatheter aortic valve replacement.
Авторы приводят первое в отечественной литературе описание клинического случая успешной транскатетерной имплантации аортального клапана у пациента высокого хирургического риска с критическим аортальным стенозом и документированной гепарининдуцированной тромбоцитопенией 2-го типа с использованием прямого ингибитора тромбина бивалирудина. Освещаются ключевые вопросы патогенеза, клинико-инструментальной диагностики гепарининдуцированной тромбоцитопении, а также существующая на сегодняшний день доказательная база применения бивалирудина в качестве препарата для управляемой интраоперационной антикоагуляции при наличии противопоказаний к гепарину.
Ключевые слова: гепарининдуцированная тромбоцитопения, бивалирудин, транскатетерная имплантация аортального клапана..
________________________________________________
In the paper the authors report the first in Russia clinical case of successful transcatheter aortic valve implantation in high-risk patient with critical aortic stenosis and verified heparin-induced thrombocytopenia type 2 with use of direct thrombin inhibitor bivalirudin. The key issues of pathogenetic and diagnostical issues of verified heparin-induced thrombocytopenia, and up-to-date clinical evidence of bivalirudin as alternative medication for the controlled procedural anticoagulation in the setting of contraindication for heparin use are highlighted in the literature review.
Key words: heparin-induced thrombocytopenia, bivalirudin, transcatheter aortic valve replacement.
Характеристики
| Авторы | А.Е. Комлев / В.В. Ромакина / Т.Э. Имаев / А.С. Колегаев / Р.С. Акчурин |
Полный текст
Список литературы
1. Warkentin TE, Greinacher A. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? Chest 2007; 132 (4): 1108–10. DOI: 10.1378/chest.07-1553
2. Datta I, Ball CG, Rudmik L et al. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. J Trauma Manag Outcomes 2010; 4: 1. DOI: 10.1186/1752-2897-4-1
3. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355 (8): 809–17. DOI: 10.1056/NEJMcp052967
4. Watson H, Davidson S, Keeling D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528–40. DOI: 10.1111/bjh.12059
5. Seigerman M, Cavallaro P, Itagaki S et al. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: An analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 2014; 28: 98–102. DOI: 10.1053/j.jvca.2013.07.021
6. Glance LG, Blumberg N, Eaton M et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery. Anesthesiology 2014; 120 (1): 62–75. DOI: 10.1097/ALN.0b013e3182a4441f
7. Matthai WH. Thrombocytopenia in Cardiovascular Patients: diagnosis and Management. Chest 2005; 127 (Suppl. 2): 46S–52S. DOI: 10.1378/chest.127.2_suppl.46S
8. Васильев С.А., Горгидзе Л.А., Моисеева Т.Н. и др. Гепарининдуцированная тромбоцитопения (обзор). Атеротромбоз. 2019; 1: 99–114. DOI: 10.21518/2307-1109-2019-1-99-114
[Vasil'ev S.A., Gorgidze L.A., Moiseeva T.N. i dr. Geparinindutsirovannaia trombotsitopeniia (obzor). Aterotromboz. 2019; 1: 99–114. DOI: 10.21518/2307-1109-2019-1-99-114 (in Russian).]
9. Марченко И.А., Шиян А.В., Андреева А.С. Современные методы лабораторной диагностики гепарин-индуцированной тромбоцитопении. Мед. совет. 2017; 12: 189–95.
[Marchenko I.A., Shiian A.V., Andreeva A.S. Sovremennye metody laboratornoi diagnostiki geparin-indutsirovannoi trombotsitopenii. Med. sovet. 2017; 12: 189–95 (in Russian).]
10. Семиголовский Н.Ю., Семиголовский С.Н. Патогенез, диагностика и лечение тромбоцитопений. Поликлиника. 2015; 7: 20–5.
[Semigolovskii N.Iu., Semigolovskii S.N. Patogenez, diagnostika i lechenie trombotsitopenii. Poliklinika.2015; 7: 20–5 (in Russian).]
11. Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340–80. DOI: 10.1378/chest.08–0677
12. Bleasel JF, Rasko JE, Rickard KA et al. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust 1992; 157 (3): 192–3.
13. Ivascu NS, Fitzgerald M, Ghadimi K et al. Heparin-induced thrombocytopenia: a review for cardiac
anesthesiologists and intensivists. J Cardiothorac Vasc Anesth 2019; 33 (2): 511–20. DOI: 10.1053/j.jvca.2018.10.035
14. Kodali SK, Williams MR, Smith CR et al. Two-year outcomes after transcatheter or surgical aorticvalve replacement. N Engl J Med 2012; 366 (18): 1686–95. DOI: 10.1056/NEJMoa1200384
15. Reardon MJ, Adams DH, Kleiman NS et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66 (2): 113–21. DOI: 10.1016/j.jacc.2015.05.017
16. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21): 2218–30. DOI: 10.1056/NEJMoa0708191
17. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21): 2203–16. DOI: 10.1056/NEJMoa062437
18. Choxi AA, Patel PA, Augoustides JG et al. Bivalirudin for cardiopulmonary bypass in the setting of heparininduced thrombocytopeniya and combined yeart and ridney transplantation-diagnostic and therapeutic Challenges. J Cardiothorac Vasc Anesth 2017; 31 (1): 354–64. DOI: 10.1053/j.jvca.2016.07.009
19. Merry AF, Raudkivi PJ, Middleton NG et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77 (3): 925–31; discussion 931. DOI: 10.1016/j.athoracsur.2003.09.061
20. Smedira NG, Dyke CM, Koster A et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131 (3): 686–92. DOI: 10.1016/j.jtcvs.2005.10.049
21. Dyke CM, Aldea G, Koster A et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84 (3): 836–9. DOI:10.1016/j.athoracsur.2007.04.007
22. Kini A, Yu J, Cohen MG et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-center registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty.
Euro Intervention 2014; 10 (3): 312–9. DOI: 10.4244/EIJV10I3A54
23. Lange P, Greif M, Bongiovanni D et al. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation. Can J Cardiol 2015; 31 (8): 998–1003. DOI: 10.1016/j.cjca.2015.02.029
24. Dangas GD, Lefevre T, Kupatt C et al. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol 2015; 66 (25): 2860–68. DOI: 10.1016/j.jacc.2015.10.003
2. Datta I, Ball CG, Rudmik L et al. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. J Trauma Manag Outcomes 2010; 4: 1. DOI: 10.1186/1752-2897-4-1
3. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355 (8): 809–17. DOI: 10.1056/NEJMcp052967
4. Watson H, Davidson S, Keeling D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528–40. DOI: 10.1111/bjh.12059
5. Seigerman M, Cavallaro P, Itagaki S et al. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: An analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 2014; 28: 98–102. DOI: 10.1053/j.jvca.2013.07.021
6. Glance LG, Blumberg N, Eaton M et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery. Anesthesiology 2014; 120 (1): 62–75. DOI: 10.1097/ALN.0b013e3182a4441f
7. Matthai WH. Thrombocytopenia in Cardiovascular Patients: diagnosis and Management. Chest 2005; 127 (Suppl. 2): 46S–52S. DOI: 10.1378/chest.127.2_suppl.46S
8. Vasil'ev S.A., Gorgidze L.A., Moiseeva T.N. i dr. Geparinindutsirovannaia trombotsitopeniia (obzor). Aterotromboz. 2019; 1: 99–114. DOI: 10.21518/2307-1109-2019-1-99-114 (in Russian).
9. Marchenko I.A., Shiian A.V., Andreeva A.S. Sovremennye metody laboratornoi diagnostiki geparin-indutsirovannoi trombotsitopenii. Med. sovet. 2017; 12: 189–95 (in Russian).
10. Semigolovskii N.Iu., Semigolovskii S.N. Patogenez, diagnostika i lechenie trombotsitopenii. Poliklinika.2015; 7: 20–5 (in Russian).
11. Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340–80. DOI: 10.1378/chest.08–0677
12. Bleasel JF, Rasko JE, Rickard KA et al. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust 1992; 157 (3): 192–3.
13. Ivascu NS, Fitzgerald M, Ghadimi K et al. Heparin-induced thrombocytopenia: a review for cardiac
anesthesiologists and intensivists. J Cardiothorac Vasc Anesth 2019; 33 (2): 511–20. DOI: 10.1053/j.jvca.2018.10.035
14. Kodali SK, Williams MR, Smith CR et al. Two-year outcomes after transcatheter or surgical aorticvalve replacement. N Engl J Med 2012; 366 (18): 1686–95. DOI: 10.1056/NEJMoa1200384
15. Reardon MJ, Adams DH, Kleiman NS et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66 (2): 113–21. DOI: 10.1016/j.jacc.2015.05.017
16. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21): 2218–30. DOI: 10.1056/NEJMoa0708191
17. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21): 2203–16. DOI: 10.1056/NEJMoa062437
18. Choxi AA, Patel PA, Augoustides JG et al. Bivalirudin for cardiopulmonary bypass in the setting of heparininduced thrombocytopeniya and combined yeart and ridney transplantation-diagnostic and therapeutic Challenges. J Cardiothorac Vasc Anesth 2017; 31 (1): 354–64. DOI: 10.1053/j.jvca.2016.07.009
19. Merry AF, Raudkivi PJ, Middleton NG et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77 (3): 925–31; discussion 931. DOI: 10.1016/j.athoracsur.2003.09.061
20. Smedira NG, Dyke CM, Koster A et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131 (3): 686–92. DOI: 10.1016/j.jtcvs.2005.10.049
21. Dyke CM, Aldea G, Koster A et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84 (3): 836–9. DOI:10.1016/j.athoracsur.2007.04.007
22. Kini A, Yu J, Cohen MG et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-center registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty.
Euro Intervention 2014; 10 (3): 312–9. DOI: 10.4244/EIJV10I3A54
23. Lange P, Greif M, Bongiovanni D et al. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation. Can J Cardiol 2015; 31 (8): 998–1003. DOI: 10.1016/j.cjca.2015.02.029
24. Dangas GD, Lefevre T, Kupatt C et al. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol 2015; 66 (25): 2860–68. DOI: 10.1016/j.jacc.2015.10.003
2. Datta I, Ball CG, Rudmik L et al. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. J Trauma Manag Outcomes 2010; 4: 1. DOI: 10.1186/1752-2897-4-1
3. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355 (8): 809–17. DOI: 10.1056/NEJMcp052967
4. Watson H, Davidson S, Keeling D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528–40. DOI: 10.1111/bjh.12059
5. Seigerman M, Cavallaro P, Itagaki S et al. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: An analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 2014; 28: 98–102. DOI: 10.1053/j.jvca.2013.07.021
6. Glance LG, Blumberg N, Eaton M et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery. Anesthesiology 2014; 120 (1): 62–75. DOI: 10.1097/ALN.0b013e3182a4441f
7. Matthai WH. Thrombocytopenia in Cardiovascular Patients: diagnosis and Management. Chest 2005; 127 (Suppl. 2): 46S–52S. DOI: 10.1378/chest.127.2_suppl.46S
8. Васильев С.А., Горгидзе Л.А., Моисеева Т.Н. и др. Гепарининдуцированная тромбоцитопения (обзор). Атеротромбоз. 2019; 1: 99–114. DOI: 10.21518/2307-1109-2019-1-99-114
[Vasil'ev S.A., Gorgidze L.A., Moiseeva T.N. i dr. Geparinindutsirovannaia trombotsitopeniia (obzor). Aterotromboz. 2019; 1: 99–114. DOI: 10.21518/2307-1109-2019-1-99-114 (in Russian).]
9. Марченко И.А., Шиян А.В., Андреева А.С. Современные методы лабораторной диагностики гепарин-индуцированной тромбоцитопении. Мед. совет. 2017; 12: 189–95.
[Marchenko I.A., Shiian A.V., Andreeva A.S. Sovremennye metody laboratornoi diagnostiki geparin-indutsirovannoi trombotsitopenii. Med. sovet. 2017; 12: 189–95 (in Russian).]
10. Семиголовский Н.Ю., Семиголовский С.Н. Патогенез, диагностика и лечение тромбоцитопений. Поликлиника. 2015; 7: 20–5.
[Semigolovskii N.Iu., Semigolovskii S.N. Patogenez, diagnostika i lechenie trombotsitopenii. Poliklinika.2015; 7: 20–5 (in Russian).]
11. Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340–80. DOI: 10.1378/chest.08–0677
12. Bleasel JF, Rasko JE, Rickard KA et al. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust 1992; 157 (3): 192–3.
13. Ivascu NS, Fitzgerald M, Ghadimi K et al. Heparin-induced thrombocytopenia: a review for cardiac
anesthesiologists and intensivists. J Cardiothorac Vasc Anesth 2019; 33 (2): 511–20. DOI: 10.1053/j.jvca.2018.10.035
14. Kodali SK, Williams MR, Smith CR et al. Two-year outcomes after transcatheter or surgical aorticvalve replacement. N Engl J Med 2012; 366 (18): 1686–95. DOI: 10.1056/NEJMoa1200384
15. Reardon MJ, Adams DH, Kleiman NS et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66 (2): 113–21. DOI: 10.1016/j.jacc.2015.05.017
16. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21): 2218–30. DOI: 10.1056/NEJMoa0708191
17. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21): 2203–16. DOI: 10.1056/NEJMoa062437
18. Choxi AA, Patel PA, Augoustides JG et al. Bivalirudin for cardiopulmonary bypass in the setting of heparininduced thrombocytopeniya and combined yeart and ridney transplantation-diagnostic and therapeutic Challenges. J Cardiothorac Vasc Anesth 2017; 31 (1): 354–64. DOI: 10.1053/j.jvca.2016.07.009
19. Merry AF, Raudkivi PJ, Middleton NG et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77 (3): 925–31; discussion 931. DOI: 10.1016/j.athoracsur.2003.09.061
20. Smedira NG, Dyke CM, Koster A et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131 (3): 686–92. DOI: 10.1016/j.jtcvs.2005.10.049
21. Dyke CM, Aldea G, Koster A et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84 (3): 836–9. DOI:10.1016/j.athoracsur.2007.04.007
22. Kini A, Yu J, Cohen MG et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-center registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty.
Euro Intervention 2014; 10 (3): 312–9. DOI: 10.4244/EIJV10I3A54
23. Lange P, Greif M, Bongiovanni D et al. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation. Can J Cardiol 2015; 31 (8): 998–1003. DOI: 10.1016/j.cjca.2015.02.029
24. Dangas GD, Lefevre T, Kupatt C et al. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol 2015; 66 (25): 2860–68. DOI: 10.1016/j.jacc.2015.10.003
________________________________________________
2. Datta I, Ball CG, Rudmik L et al. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. J Trauma Manag Outcomes 2010; 4: 1. DOI: 10.1186/1752-2897-4-1
3. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355 (8): 809–17. DOI: 10.1056/NEJMcp052967
4. Watson H, Davidson S, Keeling D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528–40. DOI: 10.1111/bjh.12059
5. Seigerman M, Cavallaro P, Itagaki S et al. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: An analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 2014; 28: 98–102. DOI: 10.1053/j.jvca.2013.07.021
6. Glance LG, Blumberg N, Eaton M et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery. Anesthesiology 2014; 120 (1): 62–75. DOI: 10.1097/ALN.0b013e3182a4441f
7. Matthai WH. Thrombocytopenia in Cardiovascular Patients: diagnosis and Management. Chest 2005; 127 (Suppl. 2): 46S–52S. DOI: 10.1378/chest.127.2_suppl.46S
8. Vasil'ev S.A., Gorgidze L.A., Moiseeva T.N. i dr. Geparinindutsirovannaia trombotsitopeniia (obzor). Aterotromboz. 2019; 1: 99–114. DOI: 10.21518/2307-1109-2019-1-99-114 (in Russian).
9. Marchenko I.A., Shiian A.V., Andreeva A.S. Sovremennye metody laboratornoi diagnostiki geparin-indutsirovannoi trombotsitopenii. Med. sovet. 2017; 12: 189–95 (in Russian).
10. Semigolovskii N.Iu., Semigolovskii S.N. Patogenez, diagnostika i lechenie trombotsitopenii. Poliklinika.2015; 7: 20–5 (in Russian).
11. Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340–80. DOI: 10.1378/chest.08–0677
12. Bleasel JF, Rasko JE, Rickard KA et al. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust 1992; 157 (3): 192–3.
13. Ivascu NS, Fitzgerald M, Ghadimi K et al. Heparin-induced thrombocytopenia: a review for cardiac
anesthesiologists and intensivists. J Cardiothorac Vasc Anesth 2019; 33 (2): 511–20. DOI: 10.1053/j.jvca.2018.10.035
14. Kodali SK, Williams MR, Smith CR et al. Two-year outcomes after transcatheter or surgical aorticvalve replacement. N Engl J Med 2012; 366 (18): 1686–95. DOI: 10.1056/NEJMoa1200384
15. Reardon MJ, Adams DH, Kleiman NS et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66 (2): 113–21. DOI: 10.1016/j.jacc.2015.05.017
16. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21): 2218–30. DOI: 10.1056/NEJMoa0708191
17. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21): 2203–16. DOI: 10.1056/NEJMoa062437
18. Choxi AA, Patel PA, Augoustides JG et al. Bivalirudin for cardiopulmonary bypass in the setting of heparininduced thrombocytopeniya and combined yeart and ridney transplantation-diagnostic and therapeutic Challenges. J Cardiothorac Vasc Anesth 2017; 31 (1): 354–64. DOI: 10.1053/j.jvca.2016.07.009
19. Merry AF, Raudkivi PJ, Middleton NG et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77 (3): 925–31; discussion 931. DOI: 10.1016/j.athoracsur.2003.09.061
20. Smedira NG, Dyke CM, Koster A et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131 (3): 686–92. DOI: 10.1016/j.jtcvs.2005.10.049
21. Dyke CM, Aldea G, Koster A et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84 (3): 836–9. DOI:10.1016/j.athoracsur.2007.04.007
22. Kini A, Yu J, Cohen MG et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-center registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty.
Euro Intervention 2014; 10 (3): 312–9. DOI: 10.4244/EIJV10I3A54
23. Lange P, Greif M, Bongiovanni D et al. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation. Can J Cardiol 2015; 31 (8): 998–1003. DOI: 10.1016/j.cjca.2015.02.029
24. Dangas GD, Lefevre T, Kupatt C et al. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol 2015; 66 (25): 2860–68. DOI: 10.1016/j.jacc.2015.10.003
Авторы
А.Е. Комлев, В.В. Ромакина*, Т.Э. Имаев, А.С. Колегаев, Р.С. Акчурин
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*dr513@mail.ru
National Medical Research Center of Cardiology, Moscow, Russia
*dr513@mail.ru
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*dr513@mail.ru
________________________________________________
National Medical Research Center of Cardiology, Moscow, Russia
*dr513@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.